Jefferies reiterates Buy on Coca-Cola Europacific stock, EUR98 target By Investing.com - ca.investing.com

Jefferies reiterated a Buy on Coca-Cola Europacific Partners with an unchanged EUR98 price target and models Q1 growth of 7.6%-8.6% (noting ~6% benefit from extra selling days), while targeting medium-term ~4% sales growth and 7% EBIT growth. The stock trades at a P/E of 18.25 (calendar-2026 P/E 17.9) with a PEG of 0.47, offers a 3.15% dividend yield (raised five consecutive years), and is executing a shareholder-friendly buyback program (499,779 shares repurchased Mar 23-27 as part of up to €1bn authorization).

Analysis

CCEP’s structural advantages — scale in distribution, concentrate economics and retail shelf relationships — mean incremental share repurchases and modest organic growth translate disproportionately into EPS and ROIC upside. Because beverage bottlers convert volume stability into cash faster than many consumer staples, a sustained 100–200bp swing in packaging or freight inflation will show up quickly in quarterly EBIT margins, making short-term volatility higher than headline stability suggests.

Second-order beneficiaries include upstream packaging and logistics suppliers; any sustained volume resilience at CCEP will support pricing power with aluminum and PET suppliers and create leverage for the company to re-negotiate transit and co-packing contracts. Conversely, smaller regional bottlers with weaker balance sheets are most exposed — they face either margin compression or dilution if forced to finance working capital or marketing to defend share.

Key near-term catalysts are margin prints driven by input-cost trajectory and the cadence of capital deployment; meaningful beats on margins or a pace of buybacks that meaningfully reduces float would likely compress the P/E gap vs. peers within 6–12 months. Main tail risks that could reverse the bullish path are a sustained spike in packaging/freight costs, an adverse FX swing in key markets, or regulatory moves (sugar taxation/labeling) that depress per-case pricing over multiple quarters.

Key Decisions for Investors

• Long CCEP stock (12-month horizon): buy shares size = 1–3% portfolio. Target +18–25% upside if margins stabilize and buyback-driven EPS accretion continues; set stop loss at -12% to guard against input-cost shocks or a missed quarter.
• Hedge via puts (protective): buy 9–12 month OTM puts at ~10–12% below current price as insurance (cost ~2–4% premium). This reduces downside risk to ~-12% net in a severe margin-compression scenario while retaining most upside.
• Relative-value pair (6–12 months): long CCEP / short a lower-quality regional bottler or staples peer trading at higher multiple (example short: KO as a hedge to US cola exposure). Position aims to capture re-rating if CCEP compresses P/E gap; size the short 50–75% of long notional to limit beta mismatch. Reward target: 1.5x risk if CCEP outperforms by 10–15%.
• Income overlay for holders (3–6 months): sell 3–6 month covered calls at 6–10% OTM to harvest yield while waiting for catalysts; if shares called away, effective realized return combines option premium + underlying gains, else repeat. Avoid if expecting a material positive catalyst within window.